inspra filmuhúðuð tafla 50 mg
upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 50 mg
inspra filmuhúðuð tafla 25 mg
upjohn eesv - eplerenonum inn - filmuhúðuð tafla - 25 mg
eplerenon bluefish filmuhúðuð tafla 50 mg
bluefish pharmaceuticals ab - eplerenonum inn - filmuhúðuð tafla - 50 mg
eplerenone alvogen filmuhúðuð tafla 25 mg
alvogen ehf. - eplerenonum inn - filmuhúðuð tafla - 25 mg
metoprolol alvogen (metoprolin) tafla 100 mg
alvogen ehf. - metoprololum tartrat - tafla - 100 mg
metoprolol alvogen (metoprolin) tafla 50 mg
alvogen ehf. - metoprololum tartrat - tafla - 50 mg
dabigatran etexilate accord
accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - blóðþurrðandi lyf - prevention of venous thromboembolic events.
firmagon
ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
xenical
cheplapharm arzneimittel gmbh - orlistat - offita - Ónæmiskerfi, þó ekki mataræði - xenical er ætlað í tengslum með dálítið hitaeiningaskert fæði í meðferð feitir sjúklinga með líkama massi (Ætti) meiri eða jafnt og 30 kg/m 2, eða offitusjúklinga (Ætti > 28 kg/m 2) með tilheyrandi hættu þáttum. meðferð með orlistat ætti að hætta eftir 12 vikur ef sjúklingarnir hafa verið ekki að missa að minnsta kosti 5% af líkama þyngd eins og mæld í upphafi meðferð.